Trial Profile
GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Entinostat (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 11 Dec 2014 Trial design presented at the 37th Annual San Antonio Breast Cancer Symposium
- 07 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Mar 2013 Planned primary completion date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.